Early tolerance and late persistence as alternative drug responses in cancer by Simona Punzi, Davide Cittaro, Guido Gatti, Gemma Crupi, Oronza A. Botrugno, Antonino Alex Cartalemi, Alon Gutfreund, Caterina Oneto, Valentina Giansanti, Chiara Battistini, Giovanni Santacatterina, Lucrezia Patruno, Ilaria Villanti, Martina Palumbo, Daniel J. Laverty, Francesca Giannese, Alex Graudenzi, Giulio Caravagna, Marco Antoniotti, Zachary Nagel, Ugo Cavallaro, Luisa Lanfrancone, Timothy A. Yap, Giulio Draetta, Nathalie Balaban, Giovanni Tonon

Get full text

Phase 2 study of pembrolizumab in patients with advanced rare cancers by Vivek Subbiah, Linghua Wang, Sara Ahmed, Michael Frumovitz, Jing Gong, Chantale Bernatchez, Siqing Fu, Aung Naing, Funda Meric-Bernstam, Shubham Pant, Nizar Tannir, Renata Ferrarotto, Joud Hajjar, Shi-Ming Tu, Mingxuan Xu, Anas Alshawa, Bettzy Stephen, Matthew Campbell, David S Hong, Sarina A Piha-Paul, Jordi Rodon Ahnert, Apostolia M Tsimberidou, Daniel D Karp, Timothy A Yap, Rivka R Colen, Vinod Ravi, Camilo Jimenez, Kanwal P Raghav, Gauri R Varadhachary, Ecaterina E Ileana Dumbrava, Sarjeel H Sabir, Saria Khan, Jeane M Painter, Abulrahman Abonofal, Richard M Simon

Get full text